LINEAGE CELL THERAPEUTICS INC LCTX 深 滬
等待開盤 09-25 09:30:00 美东时间
0.9478
-0.009
-0.93%
華盛通- 最 高0.9692
- 今 開0.9519
- 成交量 243.99万股
- 最 低 0.9101
- 昨 收 0.9567
- 總市值 2.40亿
- 52周最高 2.09
- 市盈率 靜 --
- 換手率 0.96%
- 52周最低 0.9101
- 委 比 31.25%
- 總股本 2.53亿
- 歷史最高 3.132
- 量 比 1.47
- 振 幅 6.18%
- 歷史最低 0.3651
- 每 手 1
- 風險率 0.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lineage Cell Therapeutics Updates COR1 Corneal Cell Transplant Program; Highlights Scalable Allogeneic Production Via AlloSCOPE Platform And Plans Conference Call Today
Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT COR1 Aims to Provide an "Off the Shelf" Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease Utilizes the Company’s AlloSCOPE™ 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion and...
07-13 20:08
Lineage Cell Therapeutics Q1 EPS $(0.03) Misses $(0.02) Estimate, Sales $1.725M Miss $3.602M Estimate
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 50 percent decrease over losses of $(0.02) per share
05-13 04:02
Earnings Scheduled For May 12, 2026
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines
Issued on behalf of Avaí Bio, Inc. USANewsGroup.com News Commentary VANCOUVER, BC, April 6, 2026 /PRNewswire/ -- The global cell therapy manufacturing market is on track to nearly double, fr...
04-07 01:10
Service Properties Trust, ConocoPhillips And Other Big Stocks Moving Lower In Monday's Pre-Market Session
US stock futures up, Nasdaq 100 gains 100 pts. Service Properties Trust (SVC) drops 4% in pre-market trading. Other decliners: MGRT, UP, CDZI, LCTX, KEP, AUTL, EOG, ANGX, COP.
04-06 20:03
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $9 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $9 price target.
03-24 23:19
Lineage Cell Therapeutics Expands Cell Transplant Pipeline With COR1
New Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturing ExpertiseFuchs Endothelial Corneal Dystrophy (FECD) Afflicts More Than 7.3% of the Population with a Predicted
03-24 20:07
Lineage Therap Expands ATM Equity Offering Capacity
Lineage Therap ( ($LCTX) ) has provided an announcement. On March 11, 2026, Lin...
03-11 21:51
美股大行评级 | 潜在涨幅183%！迈威尔科技获10家机构上调目标价最高至164美元；伯灵顿百货、好市多、Ciena、Samsara等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持BridgeBio Oncology"买入"评级，目标价从27美元升至29美元；韦德布什：维持WAVE Life Sciences"跑赢大市"评级，目标价从33美元升至35美元
03-09 11:47
